Two timed walk tests were found to be highly reliable for the measurement of exercise capacity in patients with mild to moderate generalized myasthenia gravis (MG), a study reports. The six-minute walk test (6MWT) and the…
Thymoma, a tumor of the thymus gland that can be benign or malignant, elevates ocular myasthenia gravis (MG) patients’ risk of developing a generalized form of the disease, a case series in Germany reported. Within two…
Robot-assisted surgery to remove the thymus gland is considered a safe method of performing a thymectomy on myasthenia gravis patients, a recent study in Singapore shows. The study, “Robotic Thymectomy in Patients With Myasthenia Gravis,…
Early support from a diverse team of clinicians is key to successfully managing pregnancy in women with myasthenia gravis, particularly if a pregnancy is complicated by pre-eclampsia, a case report highlights. The report recommends that pregnant women with the disease receive…
Treatment with Rituxan (rituximab)Â provided sustained clinical improvement, increased muscle strength, and extended the time before disease worsening in myasthenia gravis, according to researchers. It also allows myasthenia gravis (MG)Â patients who are resistant to conventional treatment to reduce their dose…
The therapeutic effects of Prograf (tacrolimus) in myasthenia gravis (MG) patients are influenced not only by dosage, but also by patients’ genetic profiles and other medications they may be taking for the disease, according to a study from China. The findings point…
People with refractory myasthenia gravis are at a higher risk of myasthenic crises and of being hospitalized compared to non-refractory patients, researchers report. Results reveal an increased disease burden in people with refractory myasthenia gravis, emphasizing the need for prevention and development of new treatment options for…
Get regular updates to your inbox.